Nagham Al-Zubidi
Overview
Explore the profile of Nagham Al-Zubidi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
150
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Williams Z, Lee A, Fraser C, Falardeau J, Subramanian P, Chen J, et al.
Front Ophthalmol (Lausanne)
. 2024 Jul;
3:1189725.
PMID: 38983058
A significant role of the neuro-ophthalmologist is to counsel patients on appropriate management and anticipated visual prognosis for conditions affecting the afferent and efferent visual systems, including those requiring neurosurgical...
2.
Hummel L, Ameri M, Alqahtani S, Sadighi Z, Al-Zubidi N
Curr Oncol
. 2024 May;
31(5):2644-2649.
PMID: 38785480
MEK inhibitors (MEKi) represent innovative and promising treatments for managing manifestations of neurofibromatosis type 1 (NF1). To mitigate potential ophthalmic side effects, such as MEKi-associated retinopathy (MEKAR), patients undergoing MEKi...
3.
Ameri M, Al-Zubidi N, Lee A
Saudi J Ophthalmol
. 2024 Apr;
38(1):25-28.
PMID: 38628415
Immunotherapy has renovated the field of oncology. Usually, cancer is treated by surgery, chemotherapy, and radiation. Immunotherapy is a promising treatment that harnesses the patient's own immune system to target...
4.
Dhanani U, Mortensen P, Raviskanthan S, Lee A, Whyte A, Gombos D, et al.
J Neuroophthalmol
. 2024 Jan;
44(4):533-539.
PMID: 38175728
Background: Multiple myeloma (MM) is a malignant disorder of plasma cells that results in tumor cells replacing the bone marrow. In extramedullary MM (EMM), however, tumor cells proliferate outside the...
5.
Ameri M, Whyte A, Raza S, Gombos D, Al-Zubidi N
J Neuroophthalmol
. 2023 Oct;
44(4):e573-e574.
PMID: 37889587
No abstract available.
6.
Hunt P, Keys P, Dalal S, Boardman D, Davila-Siliezar P, Laylani N, et al.
J Neuroophthalmol
. 2023 Aug;
44(4):e542-e543.
PMID: 37582065
No abstract available.
7.
Harish Bindiganavile S, Bhat N, Lee A, Gombos D, Al-Zubidi N
J Immunother Precis Oncol
. 2022 Jun;
4(1):6-15.
PMID: 35664825
Targeted cancer therapy agents are the latest development in cancer therapeutics. Although the spectrum of their use continues to expand, ocular side effects are frequently encountered with the use of...
8.
Lee R, Mortensen P, Raviskanthan S, Sadrameli S, Al-Zubidi N, Lee A
J Neuroophthalmol
. 2022 Apr;
43(4):e169-e170.
PMID: 35427286
No abstract available.
9.
Khimani K, Patel S, Whyte A, Al-Zubidi N
Front Oncol
. 2022 Apr;
12:806501.
PMID: 35402220
The development of immune checkpoint inhibitors (ICIs) has greatly improved survival of patients with advanced malignancies. ICIs can cause immune-related adverse effects (irAEs) involving any organ. Neurological irAEs are infrequent...
10.
Martinez-Gutierrez J, Kole M, Lopez-Rivera V, Inam M, Tang R, Al-Zubidi N, et al.
Interv Neuroradiol
. 2022 Mar;
29(4):358-362.
PMID: 35323053
Background: Venous sinus stenosis (VSS) stenting has emerged as an effective treatment for patients with Idiopathic Intracranial Hypertension (IIH). However, stenting carries risk of in-stent stenosis/thrombosis and cumulative bleeding risk...